Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent
Acute Myeloid Leukemia
Explore 588 assets in Acute Myeloid Leukemia →Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05448599CT.gov A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent (this asset) | Mabwell (Shanghai) Bioscience Co., Ltd. | P1/2 | CC · 40 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nonpapillary Renal Cell Carcinoma | — | P2 | CCC · 53 |
| Lymphoma | — | P2 | CCC · 48 |
| Myelodysplastic Syndrome | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Cd47 (Cd47 Molecule, Integrin Associated Protein, Iap, Mer6, Oa3)] And Anti-[Homo Sapiens Cd274 (Programmed Cell Death 1 Ligand 1, Pdl1, Pd-L1, B7 Homolog 1, B7H1, B7-H1, Pdcd1Lg1)], Humanized Monoclonal Antibody, Bispecific, Bivalent in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-kappa-anti-homo-sapiens-cd47-cd47-molecule-integrin-associated-protein-iap-mer6-oa3-and-anti-homo-sapiens-cd274-programmed-cell-death-1-ligand-1-pdl1-pd-l1-b7-homolog-1-b7h1-b7-h1-pdcd1lg1-humanized-monoclonal-antibody-bispecific-bivalent-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →